Answers are grounded in this paper and cite their sources.
Findings demonstrate sustained regulation of autoimmunity in NOD mice through mIL-2/CD25 treatment, indicating potential therapeutic strategies.
Highlights mIL-2/CD25 is administered to cause persistent or oscillating increases in Tregs T1D in NOD mice is fully controlled only when Treg increases persist long-term mIL-2/CD25 expands Tregs, ILC2, and NK cells; the latter two also express regulatory properties Efficacy is accompanied by a reduction in the clonal expansion of autoreactive T cells
No takes yet. Share an insight, caveat, or question.
Põder et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: